Results 31 to 40 of about 947,345 (358)
Ponatinib: a novel multi-tyrosine kinase inhibitor against human malignancies
OncoTargets and Therapy, 2019 Human malignancies are often the result of overexpressed and constitutively active receptor and non-receptor tyrosine kinases, which ultimately lead to the mediation of key tumor-driven pathways.
F. Tan +3 more
semanticscholar +1 more source
Tyrosine kinase inhibitor Tofacitinib. Safety issues
Медицинский совет, 2015 Tofacitinib (TOFA) was the first synthetic small molecule drug which was comparable with genetically engineered biological agents (GIBA) in terms of its therapeutic effect in rheumatoid arthritis (RA).
G. V. Lukina, Y. A. Sigidin
doaj +1 more source
Evidence of the presence of calcium/calmodulin-dependent protein kinase IV in human sperm and its involvement in motility regulation [PDF]
, 2005 The mechanisms involved in the regulation of mammalian sperm motility are not well understood. Calcium ions (Ca(2+)) have been suggested to play a key role in the maintenance of motility; nevertheless, how Ca(2+) modulates this process has not yet been ...
Buffone, Mariano Gabriel +6 more
core +1 more source
The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cells
Science Translational Medicine, 2019 Dasatinib is a pharmacologic switch for CARs that enables physicians to control CAR T cell function in real time. Putting CAR T cells in idle Chimeric antigen receptor, or CAR, T cells can be an effective cell therapy for cancer.
K. Mestermann +9 more
semanticscholar +1 more source
A novel protein isoform of the RON tyrosine kinase receptor transforms human pancreatic duct epithelial cells. [PDF]
, 2016 The MST1R gene is overexpressed in pancreatic cancer producing elevated levels of the RON tyrosine kinase receptor protein. While mutations in MST1R are rare, alternative splice variants have been previously reported in epithelial cancers.
Babicky, M +10 more
core +2 more sources
Haematologica, 2017 Nearly one-third of patients with acute myeloid leukemia have FMS-like tyrosine kinase 3 mutations and thus have poor survival prospects. Receptor tyrosine kinase anexelekto is critical for FMS-like tyrosine kinase 3 signaling and participates in FMS ...
Peter P. Ruvolo +11 more
doaj +1 more source
Lichen planopilaris-like eruption during treatment with tyrosine kinase inhibitor nilotinib [PDF]
Anais Brasileiros de Dermatologia, 2016 Tyrosine kinase inhibitors are effective as a target therapy for malignant neoplasms. Imatinib was the first tyrosine kinase inhibitor used. After its introduction, several other drugs have appeared with a similar mechanism of action, but less prone to ...
Juliana Ribeiro Leitão +4 more
doaj +1 more source
Essential Role of Lyn in Fibrosis. [PDF]
, 2016 Fibrotic disorders involve replacement of normal parenchyma with myofibroblasts, which deposit connective tissue, leading to obliteration of the function of the underlying organ.
Birtolo, Chiara +10 more
core +2 more sources
Haematologica, 2011 Background It has not been clearly established whether second-generation tyrosine kinase inhibitors actually improve the survival of patients with chronic myeloid leukemia in chronic phase who are given nilotinib or dasatinib therapy after treatment ...
Amr R. Ibrahim +9 more
doaj +1 more source
eJHaem, 2021 ROR1 – a receptor tyrosine kinase – is overexpressed in CLL. Ibrutinib, a Bruton's tyrosine kinase inhibitor, is clinically effective in CLL but patients may develop resistance. We evaluated the effect of an ROR1 inhibitor, KAN0441571C, in CLL cells from
Amineh Ghaderi +9 more
doaj +1 more source